Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 11

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 11
---
apeutics.com/governance/board-comittees. From time to time, our Board may establish other committees.

Compensation Committee

Our Compensation Committee consists of Mr. Guse and Mr. Clowes, who serves as the Compensation Committee’s Chairperson. Our Board has determined that both Mr. Guse and Mr. Clowes are “independent” under Nasdaq listing standards and are “non-employee directors” as defined in Rule 16b-3 promulgated under the Exchange Act, and both satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act.

The primary duties and responsibilities of our Compensation Committee as provided in the Compensation Committee charter include, among other things, overseeing our compensation policies, plans and programs and determining the compensation to be paid to our executive officers, directors and other senior management, as appropriate.

Specific responsibilities of our Compensation Committee include:

developing and implementing compensation programs for our executive officers and other employees, subject to the discretion of the full Board;

establishing base salary rates, benefits and other compensation matters for each of our executive officers;

administering our equity compensation plans;

reviewing the relationship between our performance and our compensation policies and assessing any risks associated with such policies;

reviewing and advising the Board on director compensation matters and on regional and industry-wide compensation practices and trends in order to assess the adequacy of our executive compensation programs; and

reviewing and discussing compensation related disclosures with management and making a recommendation to the Board regarding the inclusion of such disclosures in our annual proxy statement or Form 10-K, as applicable.

See the sections titled “Executive Compensation” and “Director Compensation” elsewhere in this Amendment for a description of our processes and procedures for the consideration and determination of our executive officers and directors compensation.

Audit Committee

Our Audit Committee currently consists of Mr. Clowes, Dr. van Es-Johansson and Mr. Guse, who serves as Chairperson of the Audit Committee. The Board has determined that each member of the Audit Committee is “independent” for audit committee purposes as that term is defined in the applicable Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. The Board has determined that Mr. Guse is an “audit committee financial expert” within the meaning of SEC regulations. Each member of our Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board has examined each Audit Committee member’s scope of experience and the nature of